慢性血栓栓塞性肺高血压试验中的安慰剂效应:系统性审查和元分析
Daniel Caldeira1,2,3,4, Daniel Inácio Cazeiro1, Rui Plácido1,3
1Serviço de Cardiologia, Departamento de Coração e Vasos, Centro Hospital Universitário Lisboa Norte (CHULN), Unidade Local de Saude Santa Maria, Centro Académico de Medicina de Lisboa, 1649-035 Lisboa, Portugal.
在慢性血栓栓塞性肺高血压 (CTEPH) 试验中,安慰剂效应在6分钟步行测试或生活质量中没有显著改善. 这些发现表明CTEPH的安慰剂效应很小,但并不否定安慰剂对照研究的价值.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 临床试验 临床试验
背景情况:
- 在临床试验中,安慰剂效应至关重要,但因病情而异.
- 了解慢性血栓栓塞性肺高血压 (CTEPH) 中的安慰剂效应对于试验设计至关重要.
研究的目的:
- 在CTEPH的随机对照试验中系统评估安慰剂效应.
- 量化安慰剂对CTEPH患者关键临床结果的影响.
主要方法:
- 在CTEPH中随机对照和安慰剂对照试验的系统综述.
- 在安慰剂组中对6分钟步行测试 (6MWT) 和生活质量 (EQ-5D) 的前后变化进行元分析.
- 对二次结果的分析,包括平均肺动脉压 (mPAP),肺血管阻力 (PVR),心脏指数和NT-proBNP.
主要成果:
- 分析了七项涉及270名CTEPH患者的试验,这些患者在安慰剂手臂中进行了分析.
- 在6MWT (平均差异-1.31m) 或EQ-5D得分 (平均差异-0.04) 中没有观察到统计学意义上的变化.
- 二次结局 (mPAP,PVR,心脏指数,NT-proBNP) 也显示了小效应大小的非显著变化.
结论:
- 在CTEPH临床试验中,安慰剂效应在统计学上并不显著,而且规模很小.
- 这些发现并不意味着在CTEPH中使用安慰剂对照试验在伦理上适当时无效.
- 进一步的研究可能会在特定的患者子组中完善对安慰剂反应的理解.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
The Placebo Effect
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...


